Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $79.8M | Buy |
+663,400
| New | +$76.6M | 1.58% | 17 |
|
|
2025
Q1 | – | Sell |
-829,900
| Closed | -$82.6M | – | 121 |
|
|
2024
Q4 | $82.6M | Sell |
829,900
-486,100
| -37% | -$50.1M | 1.7% | 18 |
|
|
2024
Q3 | $149M | Hold |
1,316,000
| – | – | 2.72% | 8 |
|
|
2024
Q2 | $163M | Hold |
1,316,000
| – | – | 3.22% | 8 |
|
|
2024
Q1 | $174M | Buy |
1,316,000
+261,000
| +25% | +$32.2M | 3.18% | 7 |
|
|
2023
Q4 | $115M | Hold |
1,055,000
| – | – | 2.3% | 11 |
|
|
2023
Q3 | $109M | Buy |
+1,055,000
| New | +$114M | 2.31% | 8 |
|
|
2022
Q1 | – | Sell |
-1,779,300
| Closed | -$136M | – | 157 |
|
|
2021
Q4 | $136M | Sell |
1,779,300
-1,953,100
| -52% | -$156M | 1.75% | 15 |
|
|
2021
Q3 | $280M | Hold |
3,732,400
| – | – | 3.08% | 4 |
|
|
2021
Q2 | $290M | Sell |
3,732,400
-179,155
| -5% | -$13.3M | 2.94% | 5 |
|
|
2021
Q1 | $288M | Buy |
3,911,555
+1,124,609
| +40% | +$83M | 2.69% | 7 |
|
|
2020
Q4 | $218M | Buy |
2,786,946
+73,569
| +3% | +$5.63M | 1.9% | 13 |
|
|
2020
Q3 | $215M | Hold |
2,713,377
| – | – | 2.7% | 9 |
|
|
2020
Q2 | $200M | Hold |
2,713,377
| – | – | 2.82% | 6 |
|
|
2020
Q1 | $199M | Buy |
2,713,377
+665,480
| +32% | +$52.3M | 3.35% | 5 |
|
|
2019
Q4 | $178M | Hold |
2,047,897
| – | – | 2.54% | 9 |
|
|
2019
Q3 | $164M | Sell |
2,047,897
-645,568
| -24% | -$51.7M | 3.12% | 6 |
|
|
2019
Q2 | $216M | Hold |
2,693,465
| – | – | 3.34% | 6 |
|
|
2019
Q1 | $214M | Buy |
2,693,465
+78,705
| +3% | +$5.89M | 3.31% | 7 |
|
|
2018
Q4 | $191M | Sell |
2,614,760
-1,099,771
| -30% | -$77.6M | 3.53% | 7 |
|
|
2018
Q3 | $251M | Sell |
3,714,531
-1,190,109
| -24% | -$75.8M | 3.03% | 7 |
|
|
2018
Q2 | $284M | Sell |
4,904,640
-637,394
| -12% | -$36M | 3.39% | 7 |
|
|
2018
Q1 | $288M | Buy |
5,542,034
+1,742,615
| +46% | +$94.1M | 3.57% | 4 |
|
|
2017
Q4 | $204M | Sell |
3,799,419
-1,950,957
| -34% | -$108M | 2.58% | 9 |
|
|
2017
Q3 | $351M | Hold |
5,750,376
| – | – | 3.36% | 5 |
|
|
2017
Q2 | $352M | Sell |
5,750,376
-238,839
| -4% | -$14.5M | 3.69% | 5 |
|
|
2017
Q1 | $363M | Buy |
5,989,215
+1,152,485
| +24% | +$69.9M | 4.12% | 5 |
|
|
2016
Q4 | $272M | Buy |
4,836,730
+1,161,604
| +32% | +$68M | 3.46% | 6 |
|
|
2016
Q3 | $219M | Buy |
3,675,126
+1,667,682
| +83% | +$97.5M | 2.49% | 7 |
|
|
2016
Q2 | $110M | Buy |
2,007,444
+1,786,945
| +810% | +$95.1M | 1.15% | 32 |
|
|
2016
Q1 | $11.1M | Buy |
+220,499
| New | +$10.8M | 0.12% | 88 |
|
|
2015
Q4 | – | Sell |
-434,920
| Closed | -$20.5M | – | 133 |
|
|
2015
Q3 | $20.5M | Hold |
434,920
| – | – | 0.21% | 71 |
|
|
2015
Q2 | $23.6M | Buy |
434,920
+10,480
| +2% | +$588K | 0.2% | 78 |
|
|
2015
Q1 | $23.3M | Sell |
424,440
-2,630,794
| -86% | -$149M | 0.2% | 76 |
|
|
2014
Q4 | $166M | Buy |
3,055,234
+265,458
| +10% | +$14.8M | 1.58% | 26 |
|
|
2014
Q3 | $158M | Buy |
2,789,776
+129,952
| +5% | +$7.3M | 1.65% | 23 |
|
|
2014
Q2 | $147M | Sell |
2,659,824
-9,432
| -0.4% | -$515K | 1.72% | 23 |
|
|
2014
Q1 | $145M | Hold |
2,669,256
| – | – | 1.78% | 22 |
|
|
2013
Q4 | $127M | Sell |
2,669,256
-3,698,392
| -58% | -$169M | 1.87% | 16 |
|
|
2013
Q3 | $289M | Buy |
6,367,648
+2,044,229
| +47% | +$93.3M | 5.16% | 3 |
|
|
2013
Q2 | $192M | Buy |
+4,323,419
| New | +$193M | 4.06% | 4 |
|
Other funds holding MRK
VCM
VPM
OrbiMed's MRK Position: Q1 2026 in Review
OrbiMed opened a new position in Merck (MRK) in Q1 2026: 663,400 shares worth $79.8M. The stake represents 1.58% of the portfolio and ranks #17 among its holdings. This is a return to the name: OrbiMed previously reported a position in MRK as recently as Q4 2024.
OrbiMed first reported a position in MRK in Q2 2013 and has held it in 41 quarters since. The position peaked at $363M in Q1 2017. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- OrbiMed held 663,400 shares of Merck worth $79.8M as of Q1 2026.
- Merck was a new OrbiMed position in Q1 2026.
- Merck made up 1.58% of OrbiMed's portfolio in Q1 2026, its #17 holding.
- OrbiMed first reported a position in Merck in Q2 2013 and has held it in 41 quarters since.
- OrbiMed's Merck position peaked at $363M in Q1 2017.
- 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.